Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Prescott

Showing results (511-520 of 563) with videos related to

Pageof 57
Sort By:
Circulation. Heart Failure|June 3, 2020
Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/ValsartanJames L Januzzi, Alexander Camacho, Ileana L Piña, et al.
JACC. Heart Failure|April 28, 2023
Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/ValsartanReza Mohebi, Yuxi Liu, Peder L Myhre, et al.
Clinical Pharmacology and Therapeutics|June 10, 2017
Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate HypertensionH-L Hsiao, T H Langenickel, J Petruck, et al.
Cardiovascular Therapeutics|March 19, 2016
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection FractionZhanna Kobalava, Yulia Kotovskaya, Oleg Averkov, et al.
JACC. Heart Failure|December 1, 2022
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health StatusSean P Murphy, Jonathan H Ward, Ileana L Piña, et al.
Clinical Chemistry|March 20, 2013
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trialJacob A Udell, David A Morrow, Eugene Braunwald, et al.
Journal of Cardiac Failure|September 18, 2023
Machine Learning for Proteomic Risk Scores in Heart FailureDongchu Xu, Jonathan Cunningham, Pablo-Miki Marti-Castellote, et al.
JACC. Heart Failure|February 4, 2022
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HFPeder L Myhre, Margaret F Prescott, Sean P Murphy, et al.
European Journal of Heart Failure|September 18, 2020
Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartanNasrien E Ibrahim, Ileana L Piña, Alexander Camacho, et al.
Circulation. Heart Failure|October 5, 2020
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/ValsartanNasrien E Ibrahim, Ileana L Piña, Alexander Camacho, et al.
Pageof 57

Showing results (511-520 of 563) with videos related to

Sort By:
Pageof 57
Circulation. Heart Failure|June 3, 2020
Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/ValsartanJames L Januzzi, Alexander Camacho, Ileana L Piña, et al.
JACC. Heart Failure|April 28, 2023
Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/ValsartanReza Mohebi, Yuxi Liu, Peder L Myhre, et al.
Clinical Pharmacology and Therapeutics|June 10, 2017
Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate HypertensionH-L Hsiao, T H Langenickel, J Petruck, et al.
Cardiovascular Therapeutics|March 19, 2016
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection FractionZhanna Kobalava, Yulia Kotovskaya, Oleg Averkov, et al.
JACC. Heart Failure|December 1, 2022
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health StatusSean P Murphy, Jonathan H Ward, Ileana L Piña, et al.
Clinical Chemistry|March 20, 2013
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trialJacob A Udell, David A Morrow, Eugene Braunwald, et al.
Journal of Cardiac Failure|September 18, 2023
Machine Learning for Proteomic Risk Scores in Heart FailureDongchu Xu, Jonathan Cunningham, Pablo-Miki Marti-Castellote, et al.
JACC. Heart Failure|February 4, 2022
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HFPeder L Myhre, Margaret F Prescott, Sean P Murphy, et al.
European Journal of Heart Failure|September 18, 2020
Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartanNasrien E Ibrahim, Ileana L Piña, Alexander Camacho, et al.
Circulation. Heart Failure|October 5, 2020
Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/ValsartanNasrien E Ibrahim, Ileana L Piña, Alexander Camacho, et al.
Pageof 57